Sichuan Kelun Pharmaceutical (SHE:002422), through its subsidiaries, granted Switzerland-based Windward Bio the right to commercialize a anti-thymic stromal lymphopoietin worldwide, according to a Monday filing with the Shenzhen Stock Exchange.
The anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody (mAb) SKB378/HBM93781, which is intended to treat pulmonary diseases, was developed by Harbour Biopharmaceuticals Holdings, one of the pharmaceutical company's subsidiaries that signed the commercial deal with Sichuan Kelun Botai Biopharmaceutical.
Harbour Biopharma, which is also the drug's licensor, is eligible to receive upfront and milestone payments of up to $970 million, as well as tiered royalties ranging from single-digit to double-digit percentages based on net sales. The upfront and near-term payments amount to $45 million, including cash consideration and equity in Windward Bio's parent company, the filing added.
Harbour Biopharma is also eligible to receive additional payments if Windward Bio undergoes a change in company control or enters into a sublicense agreement with a third party.
The agreement came after Windward Bio raised $200 million from its latest Series A fundraising round led by OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。